BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

27 related articles for article (PubMed ID: 8631864)

  • 1. Autophagy in the Neuronal Ceroid Lipofuscinoses (Batten Disease).
    Kim WD; Wilson-Smillie MLDM; Thanabalasingam A; Lefrancois S; Cotman SL; Huber RJ
    Front Cell Dev Biol; 2022; 10():812728. PubMed ID: 35252181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific recognition of N-acetylneuraminic acid in the GM2 epitope by human GM2 activator protein.
    Li SC; Wu YY; Sugiyama E; Taki T; Kasama T; Casellato R; Sonnino S; Li YT
    J Biol Chem; 1995 Oct; 270(41):24246-51. PubMed ID: 7592631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and specificity of human GM2 activator protein.
    Wu YY; Lockyer JM; Sugiyama E; Pavlova NV; Li YT; Li SC
    J Biol Chem; 1994 Jun; 269(23):16276-83. PubMed ID: 8206933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of GM2 activator protein with glycosphingolipids.
    Hama Y; Li YT; Li SC
    J Biol Chem; 1997 Jan; 272(5):2828-33. PubMed ID: 9006924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside.
    Sinici I; Yonekawa S; Tkachyova I; Gray SJ; Samulski RJ; Wakarchuk W; Mark BL; Mahuran DJ
    PLoS One; 2013; 8(3):e57908. PubMed ID: 23483939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the resistance of Tay-Sachs ganglioside GM2 to enzymatic degradation.
    Li YT; Li SC; Hasegawa A; Ishida H; Kiso M; Bernardi A; Brocca P; Raimondi L; Sonnino S
    J Biol Chem; 1999 Apr; 274(15):10014-8. PubMed ID: 10187778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an alternatively spliced GM2 activator protein, GM2A protein. An activator protein which stimulates the enzymatic hydrolysis of N-acetylneuraminic acid, but not N-acetylgalactosamine, from GM2.
    Wu YY; Sonnino S; Li YT; Li SC
    J Biol Chem; 1996 May; 271(18):10611-5. PubMed ID: 8631864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical consequences of mutations causing the GM2 gangliosidoses.
    Mahuran DJ
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of GM2 activator protein with glycosphingolipids.
    Li SC; Hama Y; Li YT
    Adv Exp Med Biol; 2001; 491():351-67. PubMed ID: 14533808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GM2 activator protein, its roles as a co-factor in GM2 hydrolysis and as a general glycolipid transport protein.
    Mahuran DJ
    Biochim Biophys Acta; 1998 Jul; 1393(1):1-18. PubMed ID: 9714704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GM2 gangliosidosis AB variant: first case of late onset and review of the literature.
    Ganne B; Dauriat B; Richard L; Lamari F; Ghorab K; Magy L; Benkirane M; Perani A; Marquet V; Calvas P; Yardin C; Bourthoumieu S
    Neurol Sci; 2022 Nov; 43(11):6517-6527. PubMed ID: 35925454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two patients from Turkey with a novel variant in the
    İnci A; Cengiz Ergin FB; Biberoğlu G; Okur İ; Ezgü FS; Tümer L
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):805-812. PubMed ID: 33819415
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.